Location [1]
Protein [2]
Macrophage-stimulating protein receptor beta chain
Synonyms [1]
RON, NPCA3, SEA, CD136, CDw136, PTK8

Macrophage stimulating 1 receptor (MST1R) is a gene that encodes a protein that functions as a tyrosine kinase receptor for macrophage-stimulating protein. Apart from functioning as a receptor, the protein may also be involved in host defense. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as intestinal cancer, skin cancer, and stomach cancer.

MST1R is altered in 1.62% of all cancers with colon adenocarcinoma, cutaneous melanoma, lung adenocarcinoma, breast invasive ductal carcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations [3].

MST1R GENIE Cases - Top Diseases

The most common alterations in MST1R are MST1R Mutation (1.28%), MST1R Loss (0.21%), MST1R R1178W (0.02%), MST1R R322W (0.02%), and MST1R A225T (0.01%) [3].

MST1R GENIE Cases - Top Alterations

Significance of MST1R in Diseases

Melanoma +

Gastric Adenocarcinoma +

Colorectal Carcinoma +

Malignant Uterine Neoplasm +

Bladder Carcinoma +

Urothelial Carcinoma +

Esophageal Squamous Cell Carcinoma +

Gallbladder Carcinoma +

Adenocarcinoma Of The Gastroesophageal Junction +

Malignant Solid Tumor +

Head And Neck Carcinoma +

Lung Carcinoma +

Cervical Carcinoma +

Non-Small Cell Lung Carcinoma +

Ovarian Carcinoma +

Breast Carcinoma +

Bile Duct Carcinoma +

Soft Tissue Sarcoma +

Pancreatic Carcinoma +

Bronchogenic Carcinoma +


1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.